HBM Healthcare Investments

HBM Healthcare Investments is a Swiss healthcare investment company headquartered in Zug and managed by HBM Partners. The firm invests internationally in businesses developing healthcare technologies and products, with its main areas of interest spanning biotechnology, medical technology, diagnostics, therapeutics and digital health. Its portfolio orientation is global, with a primary emphasis on the United States, Europe and China and a smaller presence in India. The company was established in July 2001 under the name HBM Bioventures AG by Henri B. Meier, a former chief financial officer of Roche. Meier served as the company's first chair of the board. The business was created around the investment view that pharmaceutical companies would increasingly rely on acquisitions of promising biotechnology businesses rather than conducting all research and development internally. At launch, the company reportedly raised close to CHF 500 million, giving it a substantial capital base for a specialist healthcare investment vehicle. HBM's investment approach is associated with emerging healthcare technologies and, according to reporting about the firm's strategy, opportunities that are generally beyond the initial seed stage but may still be relatively early in their development. The firm can invest in private companies as well as publicly traded businesses, allowing it to participate across different stages of healthcare-company formation, commercialization and public-market development. Its work is carried out by investment professionals based in Switzerland and by senior analysts and other staff in international locations including New York and Hong Kong. A significant expansion came in 2005, when HBM acquired the Swiss venture-capital firm International BM Biomedicine. This transaction strengthened the company's position in healthcare venture investing and broadened its investment platform. HBM Healthcare Investments subsequently became publicly listed on the SIX Swiss Exchange in 2008, giving investors access to a listed vehicle focused on global healthcare innovation. HBM is frequently discussed alongside BB Biotech, another Swiss-listed healthcare investment company, although the two organizations are separate businesses. HBM's identity is built around specialist investment exposure rather than the manufacture or sale of healthcare products under a consumer brand. Its offerings therefore consist primarily of investment vehicles, portfolio management and access to a diversified group of healthcare companies. At the end of March 2024, HBM reported a net asset value of slightly more than CHF 1.7 billion. This figure describes the value of the investment portfolio and related assets at that reporting date; it is not a measure of annual sales. HBM remains an active specialist investor whose performance is linked to the development, financing, commercialization and market valuation of healthcare companies worldwide.

HBM Healthcare Investments was founded in July 2001 as HBM Bioventures AG by Henri B. Meier, who had previously served as chief financial officer of Roche. Meier became the company's first chairperson of the board. The venture was established to provide investors with focused exposure to healthcare innovation, particularly biotechnology and businesses developing technologies that could attract strategic interest from larger pharmaceutical companies. The company's creation reflected a broader investment thesis about the changing structure of pharmaceutical research. Meier argued that major pharmaceutical companies would increasingly supplement or replace some internally generated research with acquisitions of promising biotechnology companies. This created a potential financing and investment opportunity for a specialized vehicle capable of identifying healthcare companies before or during their growth and commercialization phases. Contemporary accounts described the launch as having raised close to CHF 500 million. HBM expanded its platform in 2005 by acquiring International BM Biomedicine, a competing Swiss venture-capital firm. The transaction strengthened HBM's healthcare venture-investing capabilities and contributed to the development of a broader investment organization. HBM is headquartered in Zug and is managed by HBM Partners. Over time, its investment scope came to include not only biotechnology but also medical technology, diagnostics, therapeutics and digital health. The company entered the public markets in 2008 through a listing on the SIX Swiss Exchange. Its listed structure enables investors to obtain exposure to a portfolio of international healthcare businesses through a Swiss-traded investment company. HBM's portfolio has principally targeted companies in the United States, Europe and China, with additional investments in India on a smaller scale. The investment team has also developed an international operating footprint, including senior investment analysts and other personnel in New York and Hong Kong. HBM's strategy has generally been associated with emerging and growth-oriented healthcare companies. Public descriptions of its approach emphasize opportunities that are often post-seed or early-stage rather than the very earliest seed financing. Depending on the investment, HBM may participate in private companies, public companies or businesses transitioning between those stages. This gives the firm exposure to scientific development, clinical progress, regulatory events, commercialization and changes in public-market valuations. In financial reporting for the period ending in March 2024, HBM reported a net asset value of slightly more than CHF 1.7 billion. The company is often compared in financial media with BB Biotech, another Swiss-listed healthcare investment business, but HBM remains a separate organization with its own investment platform and management structure. Its brand is primarily institutional and financial rather than consumer-facing: the company offers investment exposure and portfolio management rather than medicines, devices or diagnostic products directly to end users. HBM Healthcare Investments remains active as a specialist Swiss healthcare investor. Its continuing identity is based on global sourcing, sector expertise and investment in technologies and companies that may contribute to the development of future medicines, diagnostics, devices and digital-health services.

1. 2024Net asset value exceeded CHF 1.7 billion

   The company reported a net asset value of slightly more than CHF 1.7 billion at the end of March 2024.

   Source
2. 2008Listed on the SIX Swiss Exchange

   HBM Healthcare Investments became a publicly traded company on the SIX Swiss Exchange.

   Source
3. 2005Acquisition of International BM Biomedicine

   HBM acquired the rival Swiss venture-capital firm International BM Biomedicine, expanding its healthcare investment platform.

   Source
4. 2001Founded as HBM Bioventures AG

   Henri B. Meier founded the company in July 2001 to invest in emerging healthcare and biotechnology businesses.

   Source

A specialist, globally oriented healthcare investment platform focused on emerging and growth-stage companies, particularly in biotechnology and related healthcare technologies.

• HBM Healthcare InvestmentsListed healthcare investment company2008

  HBM's principal offering is a publicly traded investment vehicle providing exposure to a diversified portfolio of international healthcare companies. The portfolio can include private and listed businesses and is concentrated in biotechnology, therapeutics, medical technology, diagnostics and digital health. The vehicle is designed for investors seeking specialist healthcare exposure rather than direct ownership of a single operating healthcare company.

• Healthcare venture and growth investmentsInvestment management2001

  HBM invests in healthcare companies at emerging, post-seed and growth stages. Its work includes identifying businesses with potentially important technologies, assessing scientific and commercial prospects, financing private companies and holding positions in public healthcare businesses. The investment focus covers the development and commercialization of medicines, diagnostics, devices and digital-health technologies across several geographic markets.

• 2008Public listing on the SIX Swiss ExchangeStrategy

  After developing its specialist healthcare investment platform, HBM moved to a listed structure.

  What changed. The company listed on the SIX Swiss Exchange, creating a publicly traded route to its healthcare portfolio.

  Aftermath. HBM became accessible to public-market investors while retaining its focus on global healthcare investments.

  Source
• 2005Acquisition of International BM BiomedicineM&A

  HBM sought to broaden its healthcare venture-investment capabilities and expand its position in the Swiss specialist investment market.

  What changed. HBM acquired International BM Biomedicine, a rival Swiss venture-capital firm.

  Aftermath. The acquisition strengthened HBM's investment platform and contributed to its broader focus across healthcare technologies.

  Source

• 2024HBM Healthcare Investments reports net asset value above CHF 1.7 billion

  HBM reported a net asset value of slightly more than CHF 1.7 billion at the end of March 2024, reflecting the scale of its global healthcare investment portfolio.

  Other
  Source
• 2022Profile of HBM's early-stage healthcare investment strategy

  A profile in Luzerner Zeitung described HBM's strategy as concentrating on healthcare opportunities that are generally beyond the seed stage while remaining relatively early in their development.

  Other
  Source
• 2020HBM's founding thesis on pharmaceutical innovation

  A Handelszeitung article revisited Henri B. Meier's founding rationale: pharmaceutical companies would increasingly acquire promising biotechnology companies as part of their research and development strategy.

  Other
  Source

1. HBM Healthcare Investments